Inve US ▾
RPRPID

Rapid Micro Biosystems (RPID) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 7, 2026

Source: earnings call transcript

Executive summary

Rapid Micro Biosystems Q2 FY26 — Record Consumables and Gross Margin Expansion

Rapid Micro Biosystems delivered a strong Q2 FY26, surpassing revenue guidance with record consumable sales and significant gross margin expansion driven by operational efficiencies. The company is seeing increasing adoption of its GrowthDirect platform, expanding its installed base and recurring revenue, and is confident in its path to positive cash flow by the end of 2028, supported by strategic partnerships and industry tailwinds. Management reaffirmed full-year revenue and placement guidance while raising validation targets.

Highlights

5

  • Total revenue increased 11% to $8.1 million, exceeding guidance.

  • Consumable revenue and units reached new quarterly records, growing over 20% year-over-year.

  • Gross margin reached a record 15% in Q2, reflecting strong execution against margin expansion strategy.

  • Full-year validation guidance was increased to at least 27 systems.

  • Recurring revenue increased 14% to $5 million, driven by installed base expansion and utilization.

Concerns

3

  • Q2 product margin was slightly below expectations at negative 3% due to timing of softer revenue.

  • Adjusted EBITDA loss for Q2 was $10.3 million, compared to a loss of $10.1 million in Q2 last year.

  • Cash usage was higher in the first half of the year due to 100% cash collection from Q4 2025 placements in the prior quarter and inventory stocking.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Total Revenue
$37M to $41M
high materiality
High
Full-year 2026 System Placements
30 to 38
high materiality
High
Full-year 2026 Validations
at least 27 systems
medium materiality
High
Q3 2026 Revenue
at least $9.5M
medium materiality
High
Q3 2026 System Placements
at least 7
medium materiality
High
Q3 2026 Gross Margin Percentage
at least 20%
medium materiality
High
Q4 2026 Gross Margin Percentage
mid to high 20% range
medium materiality
High
Full-year 2026 Total Gross Margin
approximately 20%
medium materiality
High
Full-year 2026 Product Margin
mid to high single digits
low materiality
High
Full-year 2026 Service Margin
between 45% and 50%
low materiality
High
Full-year 2026 Operating Expenses
$51M and $53M
medium materiality
High
Full-year 2026 Non-Cash Expenses
$8M
low materiality
High
Full-year 2026 Capital Expenditures
$1M
low materiality
High
Full-year 2026 Interest Income
$1M
low materiality
High
Full-year 2026 Interest Expense
$2M
low materiality
High
Cash Usage Reduction (Efficiency Program)
$1M
medium materiality
High
Cash Usage Reduction (Efficiency Program)
$3M annually
medium materiality
High
Access to Debt Tranche (Trinity Capital)
$10M
high materiality
High
Access to Debt Tranche (Trinity Capital)
another $10M
high materiality
Medium
Positive Cash Flow
positive cash flow
high materiality
High
Average Annual Revenue Growth
greater than 20%
high materiality
High
Gross Margin
50% or more
high materiality
High

Deals & partnerships

Millipore Sigma Distribution and collaboration agreement

Strategic review meeting held in Europe to advance commercial, supply chain, gross margin improvement, and technology initiatives. Leveraging Millipore Sigma's manufacturing, supply chain, and technical expertise. Opening new geographies and customer types.

Risks & headwinds

Product margin below expectations Q2 FY26

Q2 product margin was negative 3%, slightly below expectations.

Mitigation:Due to timing of some softer revenue now expected in the second half.

Higher cash usage in H1 H1 FY26

Cash usage was higher in the first half of the year.

Mitigation:Caused by 100% cash collection from Q4 2025 placements in Q4 2025 (rather than Q1 2026) and increased inventory stocking to support 2026 manufacturing plan. These factors are not expected to have a meaningful impact in H2 2026.

Delay in Millipore Sigma procurement contribution to gross margin H2 FY26

Not expected to be significant contributors in H2 2026.

Mitigation:Expected to contribute more in 2027, due to the time required for material validation and implementation.

What to watch in Q3 FY26

Millipore Sigma Contribution

second half
Current Contributed to system placements in H1 2026
Target Meaningfully increased contribution to system placements and revenue

Why it matters

The Millipore Sigma partnership is a key driver for growth, market expansion, and new customer acquisition.

what we do expect is a meaningfully increased contribution from Merck Millipore in the second half.

Find out whether RPID delivers this. Inve re-checks your case every morning.

Q&A highlights

Why was the low end of guidance not raised despite positive commentary on Millipore Sigma's increased contribution in the second half?

Management clarified that the initial low end of guidance did not include the full allocation of Millipore Sigma's commitment. While their contribution is expected to increase meaningfully in H2, it will not fully meet their annual obligation in the calendar year, but this increased contribution underpins confidence in the reaffirmed guidance.

“The low end of our guide did not include the full allocation of the Merck commitment for the year. That being said, what we do expect is a meaningfully increased contribution from Merck Millipore in the second half.”

asked by Thomas Flatton · answered by Robert Spignesi

2 min read 5 chapters

Detailed narrative

GrowthDirect System Adoption & Milestones

Rapid Micro Biosystems achieved a significant milestone with the placement of its 200th GrowthDirect system during Q2 FY26. The company also expects to ship its 10 millionth consumable in Q3, highlighting increasing adoption and routine use of the platform. Validation activity exceeded expectations, with nine systems validated in Q2 compared to two in the prior year, and the company now expects to complete at least 27 validations for the full year, providing increased visibility into future consumable revenue growth.

Commercial Strategy & Millipore Sigma Partnership

The company hosted its second North America Growth Direct Day, featuring peer-to-peer discussions on global deployments. A European event is planned for October with Merck Millipore Sigma, whose collaboration is gaining traction. Millipore Sigma contributed to system placements in H1 and is expected to increase its contribution meaningfully in H2 and into 2027, leveraging their broad reach and technical expertise to support commercial activities and margin expansion goals.

Industry Trends & Market Evolution

Customer conversations indicate a growing focus on integrating the GrowthDirect platform into broader automation, digital, and data enablement strategies. Manufacturers are seeking to improve speed, consistency, accuracy, and productivity, viewing GrowthDirect as a critical enabling technology. Encouraging activity related to U.S. reshoring and biomanufacturing capacity expansion is also noted, expected to become a meaningful growth contributor starting in 2027.

Margin Expansion Initiatives

Rapid Micro Biosystems delivered a record 15% gross margin in Q2, driven by ongoing cost reduction initiatives, manufacturing efficiencies, and service productivity improvements. The company anticipates continued sequential expansion, with Q3 gross margin expected to be at least 20% and Q4 in the mid to high 20% range. These improvements are crucial for achieving the long-term target of 50% gross margin exiting 2028 and significantly lowering cash usage.

Balance Sheet Management & Liquidity

The company ended Q2 with approximately $20 million in cash. Management expects cash usage to decline meaningfully in H2, supported by revenue growth, margin expansion, and an efficiency program projected to save $1 million in H2 2026 and $3 million annually thereafter. Rapid Micro is on track to access a $10 million debt tranche later this year, with another $10 million potentially available in mid-2027, reinforcing its pathway to positive cash flow by the end of 2028.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.